Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
IQVIA (IQV)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
$264.88+0.41%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
14.44 → 14.16 EPS · FY ending Dec 31, 2027 · 13 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 14 to 13; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for IQV yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Share repurchase authorization at $3.2 billion | It also increased share buyback authorization to $3.2 billion, showing strong capital return. | Intact | Authorization falls below $3.2 billion | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
IQV is a healthcare services growth business with a strong recent financial record and a sector backdrop that is currently supportive. Its long-term thesis is intact, with momentum improving, though management execution is a swing factor.
Valuation evidence is mixed: IQV is described as cheap versus peers, while the peer comparison also shows a 0.63 premium and an expectations gap of -0.23. The overall priced-in assessment is justified, with low fragility, so the evidence does not point to unusually fragile expectations.
Near term, recent results show strong revenue growth, higher R&D Solutions revenue, and a raised full-year 2026 outlook. Bookings and backlog support the multi-year growth case, though the latest release also records an approximately $2.1 billion backlog adjustment. Near-term risk is assessed as low for a miss, but the snapshot notes prior deep and repeated misses, making guidance credibility important.
The favorable case depends on converting R&D Solutions bookings and backlog into revenue and delivering the raised guidance. A reversal and guidance cut would damage confidence, while weaker job growth could increase recession concerns for cyclical healthcare names. Continued strong results from sector bellwethers could support the sector backdrop.
For the 1-3 year view, strong execution and a raised outlook keep IQV’s long-term thesis intact, but backlog conversion and management credibility remain key swing factors. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in IQVIA's published investment case. The stated target is >= $12.55 per share. |
| Under Pressure |
| EPS falls below $12.55 in FY26 |
Diluted EPS: $2.10 per share FY2026-Q3; GAAP. Published target: >= $12.55 per share. Annual target cannot be compared with a quarterly or TTM observation. Oct 27, 20262.1 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
R&D Solutions backlog expansion to $32.7 billion | The company expands its R&D backlog to $32.7 billion, securing future business. | Intact | R&D backlog falls below $32.4 billion | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Full-year 2026 revenue at $17.15-$17.35 billion | IQVIA grows revenue about 7% a year, with $17.25 billion guided for 2026. | Under Pressure | revenue falls below $17.15 billion in FY26 | Revenue: $4.428B FY2026-Q3; GAAP. Published target: >= $17.15 billion. Annual target cannot be compared with a quarterly or TTM observation. Oct 27, 20264,428,000,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$14.13 → $14.16 · observed estimates
$18.25B → $18.55B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $14.13 | $18,253,670,885 | 14 / 16 |
| 2026-07-25 | $14.17 | $18,278,561,230 | 22 / 20 |
| 2026-07-26 | $14.17 | $18,278,561,230 | 22 / 20 |
| 2026-07-27 | $14.17 | $18,278,561,230 | 22 / 20 |
| 2026-07-28 | $14.13 | $18,253,644,687 | 14 / 16 |
| 2026-07-29 | $14.17 | $18,278,561,230 | 22 / 20 |
| 2026-07-30 | $14.38 | $18,405,444,297 | 14 / 15 |
| 2026-07-31 | $14.38 | $18,405,444,297 | 13 / 14 |
| 2026-08-01 | $14.38 | $18,405,444,297 | 13 / 14 |
| 2026-08-02 | $14.43 | $18,463,236,560 | 21 / 18 |
| 2026-08-03 | $14.38 | $18,405,444,297 | 13 / 14 |
| 2026-08-04 | $14.44 | $18,468,806,720 | 21 / 18 |
| 2026-08-05 | $14.44 | $18,468,806,720 | 21 / 18 |
| 2026-08-06 | $14.44 | $18,468,806,720 | 21 / 18 |
| 2026-08-07 | $14.40 | $18,424,002,372 | 13 / 14 |
| 2026-08-08 | $14.44 | $18,468,826,650 | 21 / 18 |
| 2026-08-09 | $14.44 | $18,468,826,650 | 21 / 18 |
| 2026-08-10 | $14.40 | $18,424,002,372 | 13 / 14 |
| 2026-08-12 | $14.40 | $18,424,002,372 | 13 / 14 |
| 2026-08-13 | $14.40 | $18,424,002,372 | 13 / 14 |
| 2026-08-14 | $14.40 | $18,424,002,372 | 13 / 14 |
| 2026-08-15 | $14.40 | $18,424,002,372 | 13 / 14 |
| 2026-08-16 | $14.40 | $18,424,002,372 | 13 / 14 |
| 2026-08-17 | $14.40 | $18,424,002,372 | 13 / 14 |
| 2026-08-18 | $14.40 | $18,424,002,372 | 13 / 14 |
| 2026-08-19 | $14.40 | $18,424,002,372 | 13 / 14 |
| 2026-08-20 | $14.40 | $18,424,002,372 | 14 / 14 |
| 2026-08-21 | $14.40 | $18,424,002,372 | 14 / 14 |
| 2026-08-22 | $14.40 | $18,424,002,372 | 14 / 14 |
| 2026-08-23 | $14.40 | $18,424,002,372 | 14 / 14 |
| 2026-08-24 | $14.40 | $18,424,002,372 | 14 / 14 |
| 2026-08-25 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-08-26 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-08-27 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-08-28 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-08-29 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-08-30 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-08-31 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-01 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-02 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-03 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-04 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-05 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-06 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-07 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-08 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-09 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-10 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-11 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-12 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-13 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-14 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-15 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-16 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-17 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-18 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-19 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-20 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-21 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-22 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-23 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-24 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-25 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-26 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-27 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-28 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-29 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-09-30 | $14.42 | $18,424,002,372 | 14 / 14 |
| 2026-10-01 | $14.44 | $18,432,357,371 | 14 / 15 |
| 2026-10-02 | $14.44 | $18,432,357,371 | 14 / 15 |
| 2026-10-03 | $14.44 | $18,432,357,371 | 14 / 15 |
| 2026-10-04 | $14.44 | $18,432,357,371 | 14 / 15 |
| 2026-10-05 | $14.44 | $18,432,357,371 | 14 / 15 |
| 2026-10-06 | $14.42 | $18,437,915,265 | 14 / 15 |
| 2026-10-07 | $14.42 | $18,437,925,792 | 14 / 15 |
| 2026-10-08 | $14.41 | $18,437,925,792 | 14 / 16 |
| 2026-10-09 | $14.42 | $18,437,667,897 | 14 / 16 |
| 2026-10-10 | $14.42 | $18,437,667,897 | 14 / 16 |
| 2026-10-11 | $14.40 | $18,437,667,897 | 14 / 16 |
| 2026-10-12 | $14.40 | $18,437,667,897 | 14 / 16 |
| 2026-10-13 | $14.40 | $18,437,667,897 | 14 / 16 |
| 2026-10-14 | $14.40 | $18,437,667,897 | 14 / 16 |
| 2026-10-15 | $14.40 | $18,437,667,897 | 14 / 16 |
| 2026-10-16 | $14.39 | $18,438,429,875 | 14 / 16 |
| 2026-10-17 | $14.39 | $18,438,429,875 | 14 / 16 |
| 2026-10-18 | $14.38 | $18,439,203,104 | 14 / 16 |
| 2026-10-19 | $14.38 | $18,439,203,104 | 14 / 16 |
| 2026-10-20 | $14.39 | $18,439,203,104 | 14 / 16 |
| 2026-10-21 | $14.37 | $18,439,203,104 | 14 / 16 |
| 2026-10-22 | $14.37 | $18,437,650,619 | 14 / 16 |
| 2026-10-23 | $14.37 | $18,439,808,591 | 13 / 15 |
| 2026-10-24 | $14.37 | $18,439,808,591 | 13 / 15 |
| 2026-10-25 | $14.37 | $18,439,808,591 | 13 / 15 |
| 2026-10-26 | $14.37 | $18,439,641,924 | 13 / 15 |
| 2026-10-27 | $14.37 | $18,439,641,924 | 13 / 15 |
| 2026-10-28 | $14.26 | $18,497,278,927 | 13 / 14 |
| 2026-10-29 | $14.21 | $18,532,887,769 | 13 / 13 |
| 2026-10-30 | $14.21 | $18,532,887,769 | 13 / 13 |
| 2026-10-31 | $14.18 | $18,545,393,287 | 13 / 13 |
| 2026-11-01 | $14.18 | $18,545,393,287 | 13 / 13 |
| 2026-11-02 | $14.18 | $18,545,393,287 | 13 / 14 |
| 2026-11-03 | $14.16 | $18,548,171,065 | 13 / 14 |
| 2026-11-04 | $14.16 | $18,548,171,065 | 13 / 14 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 18 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 8 recorded
3 raises · 0 cuts · 0 unchanged · 2 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.